Aaron Selikson is a Litigation associate in the IP Practice of Paul Hastings. He is based in the firm’s New York office. Mr. Selikson has extensive experience litigating high-stakes patent cases across a wide range of technologies, with a particular focus on defending the patents and products of innovator pharmaceutical and biotechnology companies. He offers creative and efficient strategies to protect companies’ most valuable assets. He has helped clients enforce patent portfolios for important drug products such as Uptravi®, Lenvima®, Veletri®, Pradaxa®, Banzel®, and Uloric®.
Mr. Selikson has experience in all phases of litigation, from presuit investigations to trial and appeal. This includes developing validity and infringement strategies, drafting and arguing motions, taking and defending depositions, leading multi-jurisdictional document collection and review efforts, and working with experts in their preparation of reports, as well as preparing them for deposition and trial. Mr. Selikson has represented life sciences companies in matters involving, among others, chemical compounds, prodrugs, formulations, solid forms, methods of manufacture, synthetic processes, methods of treatment, and medical devices. He also has significant experience in post-grant proceedings, global enforcement and harmonization counseling, and patent prosecution.
- Named American Lawyer’s 2018 Transatlantic IP Team of the Year for obtaining walk-aways from six separate generic defendants for our client, Boehringer Ingelheim, in a litigation involving the blockbuster stroke drug, Pradaxa®.
- LMG Life Sciences’ Hatch Waxman Litigation Firm of the Year – Branded (2018 and 2020)
- George Washington University Law School, J.D., 2012 (with Honors, American Intellectual Property Law Association Quarterly Journal)
- Johns Hopkins University, B.S. in Chemical and Biomolecular Engineering, 2008
- Actelion Pharmaceuticals Ltd, et al. v. Zydus Worldwide DMCC, et al.: Represented Actelion, a Johnson & Johnson company, and Nippon Shinyaku in a patent infringement litigation against Zydus related to their blockbuster drug product, Uptravi®. Uptravi® is a breakthrough drug used in the treatment of pulmonary arterial hypertension to delay disease progression and hospitalization. After a multi-year litigation, Zydus agreed to a consent judgment that affirmed that the asserted claims of the patent-in-suit are valid and enforceable.
- Boehringer Ingelheim Pharma GmbH & Co. KG, et al. v. Teva Pharmaceuticals USA, Inc., et al.: Represented Boehringer Ingelheim in a litigation involving its blockbuster drug, Pradaxa®, which is a blood thinner used by patients at risk of stroke. Obtained "walk-away" consent judgments from each of the six generic drugmakers, whereby they agreed to respect the full term of the patent-in-suit and acknowledged the asserted claims were valid and infringed.
- Actelion Pharmaceuticals Ltd v. Mylan Pharmaceuticals Inc.: Currently represents Actelion, a Johnson & Johnson company, in a patent infringement litigation related to Veletri®, a critical drug for the sickest pulmonary arterial hypertension patients. After securing a favorable claim construction decision, the parties agreed to a stipulated judgment of infringement by which the District Court permanently enjoined Mylan from infringing the patents-in-suit. As part of the final judgment, which was entered shortly before the matter was set to go to trial, secured a dismissal with prejudice of Mylan’s anticipation and obviousness invalidity defenses. Mylan has appealed the District Court’s claim construction order. That appeal is ongoing.
- Eisai R&D Management Co., Ltd., et al. v. Shilpa Medicare Limited, et al.: Currently represents Eisai and Merck in a patent infringement litigation related to Lenvima®, a powerful anti-cancer drug used to treat certain forms of thyroid, liver, kidney, and endometrial cancers.
- Eisai Co., Ltd., et al. v. Glenmark Pharmaceuticals, Ltd., et al.: Represented Eisai against five generic drugmakers involving patents directed to Banzel®, an important epilepsy drug. The case settled an hour before opening arguments on favorable terms after a successful motion to exclude alleged testing evidence defendants intended to offer at trial to support their invalidity defense.
- Arena Pharmaceuticals Inc., et al. v. Lupin Ltd, et al.: Represented Eisai and Arena in a patent infringement related to the weight loss drug, Belviq®. The case settled shortly before trial on favorable terms.
- Teijin Limited, et al. v. Mylan Pharmaceuticals Inc., et al.: Represented Teijin against thirteen generic drugmakers involving patents directed to Teijin’s Uloric® drug product for gout patients. The case settled on favorable terms after a successful defense of the inventors of the patents-in-suit.